Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Sells $12,809.16 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman sold 4,284 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $12,809.16. Following the sale, the chief financial officer now owns 154,232 shares in the company, valued at $461,153.68. The trade was a 2.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Tango Therapeutics Stock Down 7.1 %

Shares of NASDAQ:TNGX opened at $3.03 on Friday. The business’s 50 day moving average is $3.12 and its 200 day moving average is $6.10. The stock has a market cap of $325.48 million, a P/E ratio of -2.57 and a beta of 0.80. Tango Therapeutics, Inc. has a 52-week low of $2.59 and a 52-week high of $12.80.

Hedge Funds Weigh In On Tango Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. State Street Corp raised its holdings in shares of Tango Therapeutics by 26.8% in the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares in the last quarter. Geode Capital Management LLC grew its holdings in Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after acquiring an additional 142,710 shares in the last quarter. Barclays PLC increased its position in Tango Therapeutics by 78.3% during the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after purchasing an additional 55,470 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after purchasing an additional 100,257 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in Tango Therapeutics during the third quarter valued at approximately $247,000. Institutional investors own 78.99% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TNGX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Guggenheim dropped their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Friday, November 8th. Finally, B. Riley cut their price objective on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics currently has an average rating of “Buy” and an average target price of $13.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.